CYP2D6 Testing and Postoperative Opioids - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CYP2D6 Testing and Postoperative Opioids

Investigators evaluate whether genotype-guided prescribing improves postoperative pain management.

  • By

  • Kathryn Wighton

  • March 9, 2026

  • 5 min

Share

CYP2D6 Testing and Postoperative Opioids

Overview

A recent randomized clinical trial evaluated the impact of CYP2D6 genotype-guided opioid prescribing on postoperative pain management. While the approach improved concordance between prescribed opioids and metabolic phenotype, it did not result in significant differences in pain intensity or opioid use compared to usual care.

Background

Postoperative pain management is critical for patient recovery and can significantly affect outcomes. The CYP2D6 enzyme plays a crucial role in opioid metabolism, and genotype-guided prescribing aims to optimize opioid selection based on individual metabolic profiles. Understanding the effectiveness of this approach is essential for improving pain management strategies in surgical patients.

Data Highlights

{'Silverman Integrated Analgesic Assessment Score': {'genotype_guided': 'Verify and correct the reported score.', 'control': 'Verify and correct the reported score.'}}

Key Findings

{'add_note': 'Include a note on the lack of significant differences in pain outcomes.'}

Clinical Implications

{'emphasize_multimodal': 'Strengthen the emphasis on multimodal pain management strategies.'}

Conclusion

{'strengthen_research_need': 'Make the need for further research more prominent.'}

Related Resources & Content

  1. CYP2D6-Guided Opioid Management and Postoperative Pain Control: A Randomized Clinical Trial | JAMA Network Open, 2023 -- CYP2D6 Testing and Postoperative Opioids
  2. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy - PMC, 2023 -- Clinical Guidelines
  3. Chronic Opioid Use Reduced by Limiting Prescribed Opioids After Surgery, Roswell Park Comprehensive Cancer Center, 2023 -- Chronic Opioid Use
  4. Assessment of Neurocognitive Function in Patients Receiving Opioid Analgesia Following Spinal Surgery, 2023 -- Neurocognitive Function
  5. Prescribing Practices of Opioids and Methadone for Infants Undergoing Surgical Treatment for Congenital Heart Disease, 2025 -- Pediatric Cardiology
  6. Hernia — CPL-01, a novel long-acting formulation of ropivacaine, shows safety and effectiveness in the repair of open inguinal hernias.
  7. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy - PMC
  8. CYP2D6-Guided Opioid Management and Postoperative Pain Control: A Randomized Clinical Trial | Pharmacy and Clinical Pharmacology | JAMA Network Open | JAMA Network

Original Source(s)

CYP2D6 Testing and Postoperative Opioids

  • by Kathryn Wighton

  • March 9, 2026

Related Content

Risks of Mobility Decline After Hip Fracture

Danish registry study found no consistent association between mobility recovery and reoperation, but mortality increased as mobility loss worsened.

Rotary Tiller Knee Dislocations Reconstructed

Two cases highlight emergency reduction, vascular assessment, single-stage reconstruction, and rehabilitation following rare agricultural injuries

PRP Linked to Better Outcomes in Advanced Knee OA

In a small open-label randomized trial, 2 platelet-rich plasma injections were associated with greater 6-month improvements in pain and function than corticosteroid injection or oral aceclofenac among patients awaiting knee arthroplasty.